August 10th 2023
Oncology nurses make the case for nurse intervention with direct-to-consumer genomic testing.
BURST CME™: Utilizing Pathology Reports to Inform Treatment Plans Across GI Cancers
View More
2022 BURST Year in Review™: Reflecting on Recent Evidence for Testing in Patients with GI Cancers
View More
2nd Annual International Congress on Pediatric Oncology
View More
2022 BURST Year in Review™: How Has Recent Evidence in Testing Elevated Outcomes in Patients with Lung Cancers
View More
Community Practice Connections™: 23rd Annual International Lung Cancer Congress®
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
Register Now!
2023 Friday Satellite Symposia: Preceding the 65th ASH Annual Meeting and Exposition
Register Now!
BURST CME™: Addressing Current Standards and Unmet Needs in Patients with Metastatic Breast Cancer
View More
20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
9th Annual School of Gastrointestinal Oncology® (SOGO®)
Register Now!
New York GU 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Register Now!
New Targets, New Treatments, and New Combinations for the Management of Advanced Prostate Cancer
View More
BURST CME™: Understanding Transfusion Dependence in Lower-Risk MDS
View More
BURST CME™: What Is the Real Risk in Lower-Risk MDS?
View More
BURST CME™: How Does Transfusion Burden Impact Real-World Outcomes in MDS?
View More
How We Do It™: Integrating Gene Fusion Testing in Oncology Clinics for Patients with NSCLC
View More
Advances In™ KRAS Inhibition: Modern Considerations In Targeting KRAS-Mutated Lung, Colorectal, And Pancreatic Cancers
View More
A Focus on Acute Myeloid Leukemia
View More
The Latest on Acute Lymphocytic Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Medical Crossfire®: Onco-Nursing Best Practices for Managing AEs Related to CAR T-Cell Therapy from Treatment Center to Community
View More
Medical Crossfire®: Key Strategies to Prioritize Testing and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care
View More
Community Practice Connections™: The Newest Frontier in HR+ Breast Cancer—Targeting ESR1 Mutations with Next-Generation Endocrine Therapy
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Medical Crossfire™: How Do We Implement Personalized Treatment for Colorectal Cancer in the Community?
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Medical Crossfire®: Exploring Hot Topics in DLBCL: Sequencing CD19-Targeted Therapies, Strategies Post-CAR T Relapse, Novel Agents, and More!
View More
Medical Crossfire®: Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Medical Crossfire®: Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Optimal Strategies Expand How Oncologists Target Treatment in NSCLC
November 29th 2018The acceptance of next-generation sequencing (NGS) platforms and cell-free DNA (cfDNA) have enabled oncologists to more specifically target genetic mutations in the treatment of patients with non–small cell lung cancer (NSCLC), according to Benjamin P. Levy, MD.
FDA Approves Larotrectinib for NTRK+ Cancers
November 27th 2018The FDA has granted an accelerated approval to larotrectinib (Vitrakvi) for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.
Precision Cancer Therapies Program Brings New Hope to Gulf Region
November 20th 2018With the inception of its Precision Cancer Therapies Program, the Ochsner Cancer Institute has been able to expand availability of early phase clinical trials to patients who might otherwise have had to drive up to 5 or 6 hours to participate in one.
Nurse Navigators Help Expand Patient Access to Genetic Counseling Services
November 9th 2018There is an increasing need for board-certified genetic counselors in the United States, says Stephanie A. Cohen, MS, LCGC, and she is looking to nurses to help improve patient access to hereditary cancer risk assessment and genetic testing.
Broad-Based Genomic Sequencing May Not Improve Survival in Patients with Lung Cancer
August 29th 2018Broad-based genomic sequencing, while useful in identifying tumor mutations in patients with non-small cell lung cancer (NSCLC), may not improve survival outcomes when compared to routine genomic testing.
FDA Approves Olaparib, a PARP Inhibitor, for BRCA+ Breast Cancer
January 12th 2018Based on results from the phase III OlympiAD trial, the FDA approved olaparib (Lynparza), a PARP inhibitor, for the treatment of patients with germline BRCA-positive, HER2-negative metastatic breast cancer who have previously received chemotherapy. HR-positive patients must also have had prior endocrine therapy.
Investigating the Use of Olaparib and Durvalumab in BRCA-mutant Breast Cancer Treatment
December 28th 2017The combination of olaparib (Lynparza) and durvalumab (Imfinzi) for pretreated patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer shows great promise for future treatment.
BRCA Gene Does Not Worsen Prognosis in Patients with Breast Cancer
January 5th 2017A recent study found that young women with breast cancer who are BRCA-positive have similar, or better, outcomes than those who do not, and that preventative bilateral mastectomy in this population does not improve the risk for recurrence or death.
Cathy Belt on How to Act on Inherited Cancer Symptoms
September 14th 2016Cathy Belt, RN, MSN, AOCN, Abramson Cancer Center of the University of Pennsylvania, discusses possible steps individuals can take upon finding out they have an inherited cancer syndrome, such as mutations in the BRCA1 or BRCA2 genes.